Literature DB >> 3558040

A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States.

G E Hanks, J J Diamond, J M Krall, K L Martz, S Kramer.   

Abstract

This report extends the follow-up of patients studied in the Patterns of Care Survey of Prostate Cancer treated in the United States between 1973 and 1975 from a maximum of 5 years to a maximum of 10 years. Survival for 60 Stage A patients was the same as expected for their age distribution (83% at 5 years and 62% at 10 years). Survival for 312 Stage B patients was 73% at 5 years and 46% at 10 years and for 296 Stage C patients was 58% at 5 years and 38% at 10 years. Infield recurrence was determined by clinical means, at 5 years 97% of Stage A patients, 86% of Stage B patients, and 74% of Stage C patients were free of local recurrence. At 10 years 97% of Stage A patients, 74% of Stage B patients, and 69% of Stage C patients remained free of local recurrence. Patients with Stage B and C cancer who developed their first failure infield show a long-term survivorship after recurrence of 40% and 20% respectively. This is in contrast to Stage B and C patients who develop a first recurrence at a metastatic site where the rate of progress to death was slower in Stage B patients than for those with Stage C disease (mean survival 32 months versus 19 months), but eventually all are dead by 7 years after recurrence. Complications were infrequent, actuarial analysis shows 93% of patients free of serious complications at 5 years and 89% free at 10 years. There were 14 patients (2%) whose complications required surgical correction and 2 of the 682 patients died of complications.

Entities:  

Mesh:

Year:  1987        PMID: 3558040     DOI: 10.1016/0360-3016(87)90063-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  The cyclotron saga.

Authors:  R H MacDougall; S J Arnott
Journal:  BMJ       Date:  1990-06-30

Review 2.  Localized prostate cancer: early intervention or expectant therapy?

Authors:  T R Griffiths; D E Neal
Journal:  J R Soc Med       Date:  1997-12       Impact factor: 5.344

Review 3.  [The hormone refractory prostate cancer - a challenge for the internal specialist].

Authors:  Stefan Kudlacek; Johannes G Meran; Dora Beke
Journal:  Wien Med Wochenschr       Date:  2007

4.  High-dose-rate intensity modulated brachytherapy with external-beam radiotherapy improves local and biochemical control in patients with high-risk prostate cancer.

Authors:  P J Prada; H González; J Fernández; P Bilbao
Journal:  Clin Transl Oncol       Date:  2008-07       Impact factor: 3.405

Review 5.  [Locally advanced prostate carcinoma (T2b-T4 N0) without and with clinical evidence of local progression (Tx N+) with lymphatic metastasis. Is radiotherapy for pelvic lymphatic metastasis indicated or not?].

Authors:  T Wiegel; W Hinkelbein
Journal:  Strahlenther Onkol       Date:  1998-05       Impact factor: 3.621

6.  Prostate cancer: results of external irradiation.

Authors:  E K Reddy; L Krishnan; S Giri; R G Evans; W K Mebust; J W Weigel
Journal:  J Natl Med Assoc       Date:  1993-02       Impact factor: 1.798

Review 7.  Cancer of the prostate.

Authors:  D P Dearnaley
Journal:  BMJ       Date:  1994-03-19

8.  Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer.

Authors:  Pedro J Prada; Lucia Mendez; José Fernández; Herminio González; Isabel Jiménez; Elisabeth Arrojo
Journal:  Radiat Oncol       Date:  2012-03-07       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.